Retatrutide

What it is

A triple-receptor agonist under clinical investigation for obesity and metabolic disease; it is not an authorized routine medicine.

Its catalogue classification is investigational gip/glp-1/glucagon receptor agonist. Status and formulation matter: a research-labelled vial is not automatically equivalent to an authorized prescription medicine containing a similarly named ingredient.

What it is studied or used for

• Body-weight outcomes in clinical trials
• Multi-receptor incretin biology
• Glucose and lipid metabolism

A research topic is not proof of a health benefit. Evidence can range from cell and animal models to controlled human trials, and those levels should not be treated as equivalent.

How it is used or administered

Human administration should occur only inside an authorized clinical trial or under an approved expanded-access pathway. Research vials are not substitutes for trial medication.

Dosing context for men and women

Why no universal number? Dose depends on the exact formulation, legal status, indication, concentration, patient factors and monitoring. Publishing a single male or female number would be misleading and unsafe.

Active shelf life and storage

What it may be paired with

Do not combine with semaglutide, tirzepatide or other incretin medicines outside a trial. Overlapping gastrointestinal, glycaemic and pancreatic risks may occur.

Continue with primary sources

Evidence and regulatory status change. Verify the exact active ingredient, formulation and jurisdiction before drawing conclusions.